The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
Open accessAbstract
OBJECTIVE: To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest evidence in the literature. METHODS: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness method was used to develop consensus recommendations pertaining to 7 treatment topics. In February 2019, the international panel was reconvened with the addition of one member to represent South America. All previous recommendations were reviewed for currency, and new consensus recommendations were developed on topics that required inclusion or updates based on the recent literature. Up to 3 rounds of anonymous e-mail votes were used to reach consensus, with modifications to recommendations between rounds based on the panel input. A simple majority vote (80% of panel members voting "yes") was used to approve minor changes in grammar and syntax to improve clarity. RESULTS: The previous recommendations for thymectomy were updated. New recommendations were developed for the use of rituximab, eculizumab, and methotrexate as well as for the following topics: early immunosuppression in ocular MG and MG associated with immune checkpoint inhibitor treatment. CONCLUSION: This updated formal consensus guidance of international MG experts, based on new evidence, provides recommendations to clinicians caring for patients with MG worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Myasthenia gravis: Recommendations for clinical research standards
Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, Jaretzki, A., Barohn, R. J., Ernstoff, R. M., Kaminski, H. J., Keesey, J. C., Penn, A. S., & Sanders, D. B. (2000) · Neurology · doi:10.1212/wnl.55.1.16 · Cited by 1,651
Self-citationInternational consensus guidance for management of myasthenia gravis: Executive summary
Sanders, D. B., Wolfe, G. I., Benatar, M., Evoli, A., Gilhus, N. E., Illa, I., Kuntz, N., Massey, J. M., Melms, A., Murai, H., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002790 · Cited by 1,212
Self-citationRandomized Trial of Thymectomy in Myasthenia Gravis
Wolfe, G. I., Kaminski, H. J., Aban, I., Minisman, G., Kuo, H., Marx, A., Ströbel, P., Mazia, C. G., Oger, J. J.-F., Cea, G., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602489 · Cited by 1,011
Self-citationHoward, J. F., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Burns, T. M., Kissel, J. T., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30369-1 · Cited by 845
Self-citationRother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · cited 1×
“Eculizumab prevents the formation of the membrane attack complex and reduces damage caused by complement-fixing AChR antibodies.(36) In a phase II crossover RCT of 14 patients with refractory generalized AChRAb + MG, at the end of the first treatment period, 6/7 (86%) of eculizumab-treated patients achieved the primar…”
ResultMyasthenia gravis: recommendations for clinical research standards
Jaretzki, A., Barohn, R. J., Ernstoff, R. M., Kaminski, H. J., Keesey, J. C., Penn, A. S., & Sanders, D. B. (2000) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(00)01595-2 · Cited by 648
Self-citationNivolumab-related myasthenia gravis with myositis and myocarditis in Japan
Suzuki, S., Ishikawa, N., Konoeda, F., Seki, N., Fukushima, S., Takahashi, K., Uhara, H., Hasegawa, Y., Inomata, S., Otani, Y., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004359 · Cited by 392
Safa, H., Johnson, D. H., Trinh, V. A., Rodgers, T. E., Lin, H., Suarez-Almazor, M. E., Fa’ak, F., Saberian, C., Yee, C., Davies, M. A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0774-y · Cited by 312
Cited by
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations
Dresser, L., Wlodarski, R., Rezania, K., & Soliven, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112235 · Cited by 475
Howard, J. F., Bresch, S., Genge, A., Hewamadduma, C., Hinton, J., Hussain, Y., Juntas-Morales, R., Kaminski, H. J., Maniaol, A., Mantegazza, R., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00080-7 · Cited by 281
Self-citation
Metadata
- Authors
- Narayanaswami, P., Sanders, D. B., Wolfe, G., Benatar, M., Cea, G., Evoli, A., Gilhus, N. E., Illa, I., Kuntz, N. L., Massey, J., Melms, A., Murai, H., Nicolle, M., Palace, J., Richman, D., & Verschuuren, J.
- Venue
- Neurology
- Published
- 2021-01-19
- Volume
- 96
- Issue
- 3
- Pages
- 114-122
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W3094785429
- Cited by
- 813
- References
- 35
- FWCI
- 24.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. https://app.cochat.ai/papers/10.1212/wnl.0000000000011124
- The paper
- Narayanaswami, P., Sanders, D. B., Wolfe, G., Benatar, M., Cea, G., Evoli, A., Gilhus, N. E., Illa, I., Kuntz, N. L., Massey, J., Melms, A., Murai, H., Nicolle, M., Palace, J., Richman, D., & Verschuuren, J. (2021). International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. https://doi.org/10.1212/wnl.0000000000011124
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.